AVXS News
Archived Headlines
- Biotechs lean heavily on insider buying to complete quasi-IPOs 02/11/16
- AveXis prices upsized IPO at $20 midpoint 02/10/16
- Week ahead: Two large and levered IPOs take center stage to raise $1 billion 02/05/16
- Making rare diseases rarer: Gene therapy biotech AveXis sets terms for $85 million IPO 02/01/16
- US IPO Weekly Recap: The only IPO delays as the market falls for the second straight week 01/15/16
See more
Big biotech swings: 2016 IPO AveXis pops 82%, 2018 IPO Menlo drops 77%
• ...read more
Bigger and better: 2016 IPOs that raised more than $100 million are up over 30%
The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue,...read more
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
US IPO Weekly Recap: IPO market largely closed; two biotechs go public and break
The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%. With markets...read more